Maze Therapeutics, Inc.
MAZENASDAQHealthcare● Active
$23.81
$-0.46(-1.90%)
Market Cap$1.3B
P/E Ratio—
52W High$53.65
52W Low$9.83
Maze Therapeutics, Inc. (MAZE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MAZE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.45
Est. -$0.43 · -4.7%
Revenue
$0.02B
Est. $0.01B · +88.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
MAZE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.76 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.43 | -$0.45 | -4.7% | $0.02B | $0.01B | +88.2% |
| ▲ Q1 FY2026 | Mar 25, 2026 | -$0.73 | -$0.65 | +11.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.74 | -$0.66 | +10.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.79 | -$0.77 | +2.5% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.76 | -$1.15 | -51.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | $0.45 | -$18.32 | -4171.1% | — | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | -$0.57 | — | $0.00B | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.76
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.45
EPS Est.
-$0.43
EPS Surpr.
-4.7%
Revenue
$0.02B
Q1 FY2026
Mar 25, 2026Beat
EPS Actual
-$0.65
EPS Est.
-$0.73
EPS Surpr.
+11.0%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.66
EPS Est.
-$0.74
EPS Surpr.
+10.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.77
EPS Est.
-$0.79
EPS Surpr.
+2.5%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$1.15
EPS Est.
-$0.76
EPS Surpr.
-51.3%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$18.32
EPS Est.
$0.45
EPS Surpr.
-4171.1%
Revenue
—
Q3 FY2024
Sep 30, 2024
EPS Actual
-$0.57
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.87 | $-0.87 | $-0.87 | 2 |
| Q3 FY2027 | $-0.83 | $-0.83 | $-0.83 | 2 |
| Q2 FY2027 | $-0.83 | $-0.83 | $-0.83 | 2 |
| Q1 FY2027 | $-0.84 | $-0.84 | $-0.84 | 2 |
| Q4 FY2026 | $-0.79 | $-0.79 | $-0.79 | 4 |
| Q3 FY2026 | $-0.85 | $-0.76 | $-0.67 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -4.7% | $25.52 | $25.78 | +1.02% |
| ▲ Q1 FY2026 | Mar 25, 2026 | +11.0% | $49.00 | $31.73 | -35.24% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +10.8% | $30.27 | $29.63 | -2.11% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +2.5% | $13.47 | $13.74 | +2.00% |
| ▼ Q2 FY2025 | May 14, 2025 | -51.3% | $9.86 | $9.06 | -8.11% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -4171.1% | $11.42 | $11.01 | -3.59% |
| — Q3 FY2024 | Sep 30, 2024 | — | No price data | $15.95 | — |
| — Q2 FY2024 | Jun 30, 2024 | — | No price data | $15.95 | — |
Q2 FY2026+1.02%
Report Date
May 12, 2026
EPS Beat/Miss
-4.7%
Price Before
$25.52
Price After
$25.78
Q1 FY2026-35.24%
Report Date
Mar 25, 2026
EPS Beat/Miss
+11.0%
Price Before
$49.00
Price After
$31.73
Q4 FY2025-2.11%
Report Date
Nov 6, 2025
EPS Beat/Miss
+10.8%
Price Before
$30.27
Price After
$29.63
Q3 FY2025+2.00%
Report Date
Aug 12, 2025
EPS Beat/Miss
+2.5%
Price Before
$13.47
Price After
$13.74
Q2 FY2025-8.11%
Report Date
May 14, 2025
EPS Beat/Miss
-51.3%
Price Before
$9.86
Price After
$9.06
Q1 FY2025-3.59%
Report Date
Mar 31, 2025
EPS Beat/Miss
-4171.1%
Price Before
$11.42
Price After
$11.01
Q3 FY2024—
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$15.95
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$15.95
Avg Beat Reaction-11.78%
Avg Miss Reaction-3.56%
Beat Rate3 / 8 quarters
Largest Move-35.24% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MAZE ends December
Maze Therapeutics, Inc. (MAZE) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.45 — missing the analyst consensus of $-0.43 by -4.7%. The next MAZE earnings date is expected around September 1, 2026.
Each quarter, investors track MAZE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MAZE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MAZE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MAZE earnings · 5 questionsMaze Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MAZE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MAZE historically reports after market close (AMC).
MAZE earnings datewhen is MAZE earningsMAZE next earnings datewhen does MAZE report earningsMAZE earnings calendar
▸ Source: FMP · Maze Therapeutics, Inc. SEC filings · US GAAP · Maze Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026